Rukan Daccak, MD
Gastroenterology · Pasadena, TXNPI 1780629840
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Conmed Corporation at 39.0% of the total. Reporting peaked in 2021 at $1,326 and has fallen 79.6% since, to $271 in 2025. That places this record below the midpoint for gastroenterology clinicians in TX, where the typical reported total is $3,104.
Across 75 payments — averaging $44.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Conmed Corporation$1K
- Janssen Research & Development, LLC$632
- AbbVie$622
- Gilead$201
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$111
- Madrigal Pharmaceuticals$86
- plus $399 from 14 others
Across 137 payments — averaging $6818.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$775K
- Eli Lilly$66K
- Boehringer Ingelheim International GmbH$51K
- Janssen Research & Development, LLC$24K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
- Intercept Pharmaceuticals, Inc.$5K
- plus $4K from 2 others
What the payments were for
- Consulting fees$1,25737%
- Travel & lodging$52316%
- Food & beverage$1,58047%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Conmed Corporation | 3 | $1,310 |
| Janssen Research & Development, LLC | 5 | $632 |
| AbbVie | 21 | $622 |
| Gilead | 11 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $111 |
| Madrigal Pharmaceuticals | 3 | $86 |
| QOL Medical, LLC | 5 | $54 |
| Ironwood Pharmaceuticals, Inc | 2 | $47 |
| Novo Nordisk | 2 | $43 |
| Vivus LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Merck | 1 | $29 |
| Redhill Biopharma Inc. | 2 | $29 |
| Shionogi Inc | 1 | $26 |
| Romark Laboratories, LC | 3 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Vibrant Gastro, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEAMER SYSTEM$1,236
- Tremfya$523
- Mavyret$233
How this compares
$3,360 in reported general payments places this provider in the 50th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 12 | $35,830 |
| LinzessLinaclotide | 33 | $33,311 |
| Tetracycline Hcl | 43 | $8,988 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 104 | $6,000 |
| Famotidine | 159 | $2,897 |
| Pantoprazole Sodium | 301 | $2,397 |
| Dicyclomine Hcl | 42 | $1,741 |
| Omeprazole | 46 | $1,081 |
| Clarithromycin | 27 | $891 |
| Metronidazole | 93 | $728 |
| Celecoxib | 11 | $470 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $320 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 44 | $267 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $208 |
| Lactulose | 27 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $111 | $35,83012 claims |
| AbbVieLinzess | $622 | $33,31133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Pasadena
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.